On December 10, 2020, the Supreme Court of Canada dismissed Pfizer’s application for leave to appeal (Docket No. 39150) a decision upholding an interlocutory decision on a question relevant to the assessment of section 8 damages related to pregabalin (Pfizer’s LYRICA). As previously reported, the Federal Court of Appeal dismissed Pfizer’s appeal from the Federal Court decision holding that Pfizer’s defence of ex turpi causa by reason of infringement was not legally viable as Pfizer did not bring an infringement action against Pharmascience in the real world.
Should you have any questions, please do not hesitate to contact a member of the Life Sciences Regulatory & Compliance Group.
The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.
Related Publications & Articles
-
FCA provides guidance on standard for leave to appeal interlocutory PMNOC decisions
On December 3, 2020, the Federal Court of Appeal released its first decision providing guidance on the standard for obtaining leave to appeal interlocutory decisions under section 6.11(1) of the Paten...Read More -
2020 Highlights in Canadian Life Sciences IP and Regulatory Law
In 2020, Rx IP Update reported on a number of developments in Canadian life sciences IP and regulatory law.Read More -
Federal Court decision regarding glatiramer acetate finds one patent obvious and another valid and infringed
On January 6, 2021, the Federal Court issued its decision in two patent infringement actions pursuant to subsection 6(1) of the Patented Medicines (Notice of Compliance) Regulations involving Teva’s p...Read More